
Opinion|Videos|May 8, 2024
Integrating New PAH Therapies into Clinical Practice
An expert on pulmonary arterial hypertension discusses how sotatercept might fit into current treatment paradigms and key factors that should guide clinical decision-making.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Sotatercept, a new treatment for PAH, recently received FDA approval in April 2024. How do you see this new therapy, as well as other emerging pulmonary arterial hypertension (PAH) treatments, fitting into the current treatment paradigm for PAH?
- What key factors should guide clinicians in determining the appropriate use of these new therapies in clinical practice?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Government Shutdown Concluded but ACA Subsidies in Limbo
2
Cefdinir Nearly Doubles Outpatient Uncomplicated UTI Treatment Failure Compared With Cephalexin
3
FDA Approves Ziftomenib for R/R NPM1-Mutated AML
4
Stronger Carer-Child Bonds Don’t Predict Later Mental Health
5

















































